Evaluating the influence of common antibiotics on the efficacy of a recombinant immunotoxin in tissue culture
- PMID: 31133049
- PMCID: PMC6537151
- DOI: 10.1186/s13104-019-4337-6
Evaluating the influence of common antibiotics on the efficacy of a recombinant immunotoxin in tissue culture
Abstract
Objective: Recombinant immunotoxins (RITs) are antibody-toxin fusion proteins that can selectively eliminate populations of cells expressing specific surface receptors. They are in evaluation as therapeutic agents for cancer. RITs based on Pseudomonas exotoxin A (PE) are in use clinically for the treatment of hairy cell leukemia, and under trial for the treatment of other cancers. In an effort to improve the efficacy of PE-based RITs, we evaluated the potential of combination therapy with several common antibiotics (tetracycline, chloramphenicol, streptomycin, linezolid, fusidic acid, and kanamycin) on human cell lines HEK293, OVCAR8, and CA46. Antibiotics were selected based on their potential to inhibit mitochondrial protein synthesis and disrupt energy metabolism in cancer cells.
Results: Tetracycline, chloramphenicol, linezolid, and fusidic acid alone killed cultured human cells at high concentrations. At high but nontoxic concentrations of each antibiotic, only chloramphenicol treatment of the Burkitt's lymphoma cell line CA46 showed enhanced cytotoxicity when paired with an anti-transferrin receptor/PE RIT. This result, however, could not be replicated in additional Burkitt's lymphoma cell lines Ramos and Raji. Although the six antibiotics we tested are not promising candidates for RIT combination therapy, we suggest that fusidic acid could be considered independently as a potential cancer therapeutic.
Keywords: Antibiotics; Combination therapy; Cytotoxicity; HB21-LR; Mitochondrial translation; Pseudomonas exotoxin A; Recombinant immunotoxins; Translation inhibition.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures

Similar articles
-
Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A.Bioconjug Chem. 2015 Jun 17;26(6):1120-8. doi: 10.1021/acs.bioconjchem.5b00190. Epub 2015 Jun 3. Bioconjug Chem. 2015. PMID: 25997032 Free PMC article.
-
Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A.Toxins (Basel). 2016 Jul 25;8(8):217. doi: 10.3390/toxins8080217. Toxins (Basel). 2016. PMID: 27463727 Free PMC article.
-
Preparation of Diphtheria and Pseudomonas Exotoxin A Immunotoxins and Evaluation of Their Cytotoxicity Effect on SK-BR-3, BT-474, and MDA-MB-231 Breast Cancer Cell Lines.Cancer Invest. 2019;37(10):546-557. doi: 10.1080/07357907.2019.1655761. Epub 2019 Oct 10. Cancer Invest. 2019. PMID: 31597492
-
A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.FEBS J. 2011 Dec;278(23):4683-700. doi: 10.1111/j.1742-4658.2011.08182.x. Epub 2011 Jun 2. FEBS J. 2011. PMID: 21585657 Free PMC article. Review.
-
Pseudomonas exotoxin and recombinant immunotoxins derived from it.Ann N Y Acad Sci. 1993 Jun 23;685:740-5. doi: 10.1111/j.1749-6632.1993.tb35935.x. Ann N Y Acad Sci. 1993. PMID: 8363279 Review.
Cited by
-
Intracellular trafficking of furin enhances cellular intoxication by recombinant immunotoxins based on Pseudomonas exotoxin A.Biol Open. 2025 Jun 15;14(6):bio061792. doi: 10.1242/bio.061792. Epub 2025 Jun 20. Biol Open. 2025. PMID: 40485510 Free PMC article.
-
Selective toxicity of antibacterial agents-still a valid concept or do we miss chances and ignore risks?Infection. 2021 Feb;49(1):29-56. doi: 10.1007/s15010-020-01536-y. Epub 2020 Dec 23. Infection. 2021. PMID: 33367978 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical